Novartis International AG / Novartis Pharma AG / Pharmaceuticals Corporation / Novartis Group / Novartis AG / Osteoporosis / /
Continent
Europe / /
Country
Switzerland / Norway / United States / Brazil / Iceland / Canada / /
Currency
USD / EUR / / /
Event
FDA Phase / /
Facility
Leuven University Centre / /
IndustryTerm
treatment of osteoporosis / consumer health products / healthcare / treatment of Paget’s disease / pharmaceuticals / diagnostic tools / osteoporosis treatment / healthcare solutions / /
MedicalCondition
woman’s disease / common metabolic bone disorder / only osteoporosis / muscle pain / postmenopausal osteoporosis / fever / Paget’s disease / osteoporosis / /
Organization
Food and Drug Administration / Division of Geriatric Medicine in Belgium / North America Office / Committee for Medicinal Products for Human Use / US Securities and Exchange Commission / Medicare / Aclasta administration / European Commission / EU Commission / European Union / Leuven University Centre for Metabolic Bone Diseases / International Osteoporosis Foundation / /
Person
Richard Jarvis Jill Pozarek Edwin Valeriano / Steven Boonen / Trevor Mundel / Eric Althoff / Irina Ferluga / Ruth Metzler-Arnold / Thomas Hungerbuehler Isabella Zinck / / /
Position
general public pricing pressures / Global Head of Development Functions / Professor of Medicine / /
Novartis International AG Novartis Global Communications CH-4002 Basel